MedTrace Logo

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

NCT05624944 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2025-02-28

No results posted yet for this study

Summary

This is an open-label pharmacokinetic study of TS-142 in patients with hepatic impairment

Conditions

  • Patients with Mild or Moderate Hepatic Impairment

Interventions

DRUG

TS-142 5 mg

Single-dose of 5 mg of TS-142

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-26
Primary Completion
2023-12-05
Completion
2023-12-05

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05624944 on ClinicalTrials.gov